0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Gene Therapy for Sickle Cell Disease Market Research Report 2024
Published Date: October 2024
|
Report Code: QYRE-Auto-9V18477
Home | Market Reports | Health| Health Conditions| Genetic Disorders
Global Gene Therapy for Sickle Cell Disease Market Research Report 2024
BUY CHAPTERS

Global Gene Therapy for Sickle Cell Disease Market Research Report 2024

Code: QYRE-Auto-9V18477
Report
October 2024
Pages:71
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Gene Therapy for Sickle Cell Disease Market

Gene therapy for sickle cell disease is a treatment that aims to correct the genetic mutation responsible for producing abnormal hemoglobin, which leads to sickle-shaped red blood cells. This process involves extracting the patient's hematopoietic stem cells, introducing a functional copy of the β-globin gene to restore normal hemoglobin production, and reinfusing the modified cells back into the patient.The goal is to alleviate symptoms and complications of the disease, such as pain crises and anemia, potentially offering a long-term cure for affected individuals.
The global Gene Therapy for Sickle Cell Disease market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Gene Therapy for Sickle Cell Disease is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Gene Therapy for Sickle Cell Disease is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Gene Therapy for Sickle Cell Disease in Children and Adolescents is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Gene Therapy for Sickle Cell Disease include Vertex Pharmaceuticals, Bluebird bio, Editas Medicine, CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy for Sickle Cell Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy for Sickle Cell Disease.
The Gene Therapy for Sickle Cell Disease market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gene Therapy for Sickle Cell Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Therapy for Sickle Cell Disease companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Gene Therapy for Sickle Cell Disease Market Report

Report Metric Details
Report Name Gene Therapy for Sickle Cell Disease Market
Segment by Type
  • Gene Addition Therapies
  • Gene Editing Therapies
  • Others
Segment by Application
  • Children and Adolescents
  • Adults
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Vertex Pharmaceuticals, Bluebird bio, Editas Medicine, CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Gene Therapy for Sickle Cell Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Gene Therapy for Sickle Cell Disease Market report?

Ans: The main players in the Gene Therapy for Sickle Cell Disease Market are Vertex Pharmaceuticals, Bluebird bio, Editas Medicine, CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics

What are the Application segmentation covered in the Gene Therapy for Sickle Cell Disease Market report?

Ans: The Applications covered in the Gene Therapy for Sickle Cell Disease Market report are Children and Adolescents, Adults

What are the Type segmentation covered in the Gene Therapy for Sickle Cell Disease Market report?

Ans: The Types covered in the Gene Therapy for Sickle Cell Disease Market report are Gene Addition Therapies, Gene Editing Therapies, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Therapy for Sickle Cell Disease Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Gene Addition Therapies
1.2.3 Gene Editing Therapies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Gene Therapy for Sickle Cell Disease Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Children and Adolescents
1.3.3 Adults
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy for Sickle Cell Disease Market Perspective (2019-2030)
2.2 Global Gene Therapy for Sickle Cell Disease Growth Trends by Region
2.2.1 Global Gene Therapy for Sickle Cell Disease Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Gene Therapy for Sickle Cell Disease Historic Market Size by Region (2019-2024)
2.2.3 Gene Therapy for Sickle Cell Disease Forecasted Market Size by Region (2025-2030)
2.3 Gene Therapy for Sickle Cell Disease Market Dynamics
2.3.1 Gene Therapy for Sickle Cell Disease Industry Trends
2.3.2 Gene Therapy for Sickle Cell Disease Market Drivers
2.3.3 Gene Therapy for Sickle Cell Disease Market Challenges
2.3.4 Gene Therapy for Sickle Cell Disease Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy for Sickle Cell Disease Players by Revenue
3.1.1 Global Top Gene Therapy for Sickle Cell Disease Players by Revenue (2019-2024)
3.1.2 Global Gene Therapy for Sickle Cell Disease Revenue Market Share by Players (2019-2024)
3.2 Global Gene Therapy for Sickle Cell Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Gene Therapy for Sickle Cell Disease Revenue
3.4 Global Gene Therapy for Sickle Cell Disease Market Concentration Ratio
3.4.1 Global Gene Therapy for Sickle Cell Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy for Sickle Cell Disease Revenue in 2023
3.5 Global Key Players of Gene Therapy for Sickle Cell Disease Head office and Area Served
3.6 Global Key Players of Gene Therapy for Sickle Cell Disease, Product and Application
3.7 Global Key Players of Gene Therapy for Sickle Cell Disease, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Therapy for Sickle Cell Disease Breakdown Data by Type
4.1 Global Gene Therapy for Sickle Cell Disease Historic Market Size by Type (2019-2024)
4.2 Global Gene Therapy for Sickle Cell Disease Forecasted Market Size by Type (2025-2030)
5 Gene Therapy for Sickle Cell Disease Breakdown Data by Application
5.1 Global Gene Therapy for Sickle Cell Disease Historic Market Size by Application (2019-2024)
5.2 Global Gene Therapy for Sickle Cell Disease Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Gene Therapy for Sickle Cell Disease Market Size (2019-2030)
6.2 North America Gene Therapy for Sickle Cell Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Gene Therapy for Sickle Cell Disease Market Size by Country (2019-2024)
6.4 North America Gene Therapy for Sickle Cell Disease Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Therapy for Sickle Cell Disease Market Size (2019-2030)
7.2 Europe Gene Therapy for Sickle Cell Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Gene Therapy for Sickle Cell Disease Market Size by Country (2019-2024)
7.4 Europe Gene Therapy for Sickle Cell Disease Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size (2019-2030)
8.2 Asia-Pacific Gene Therapy for Sickle Cell Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size by Region (2019-2024)
8.4 Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gene Therapy for Sickle Cell Disease Market Size (2019-2030)
9.2 Latin America Gene Therapy for Sickle Cell Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Gene Therapy for Sickle Cell Disease Market Size by Country (2019-2024)
9.4 Latin America Gene Therapy for Sickle Cell Disease Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy for Sickle Cell Disease Market Size (2019-2030)
10.2 Middle East & Africa Gene Therapy for Sickle Cell Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Gene Therapy for Sickle Cell Disease Market Size by Country (2019-2024)
10.4 Middle East & Africa Gene Therapy for Sickle Cell Disease Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Vertex Pharmaceuticals
11.1.1 Vertex Pharmaceuticals Company Details
11.1.2 Vertex Pharmaceuticals Business Overview
11.1.3 Vertex Pharmaceuticals Gene Therapy for Sickle Cell Disease Introduction
11.1.4 Vertex Pharmaceuticals Revenue in Gene Therapy for Sickle Cell Disease Business (2019-2024)
11.1.5 Vertex Pharmaceuticals Recent Development
11.2 Bluebird bio
11.2.1 Bluebird bio Company Details
11.2.2 Bluebird bio Business Overview
11.2.3 Bluebird bio Gene Therapy for Sickle Cell Disease Introduction
11.2.4 Bluebird bio Revenue in Gene Therapy for Sickle Cell Disease Business (2019-2024)
11.2.5 Bluebird bio Recent Development
11.3 Editas Medicine
11.3.1 Editas Medicine Company Details
11.3.2 Editas Medicine Business Overview
11.3.3 Editas Medicine Gene Therapy for Sickle Cell Disease Introduction
11.3.4 Editas Medicine Revenue in Gene Therapy for Sickle Cell Disease Business (2019-2024)
11.3.5 Editas Medicine Recent Development
11.4 CRISPR Therapeutics
11.4.1 CRISPR Therapeutics Company Details
11.4.2 CRISPR Therapeutics Business Overview
11.4.3 CRISPR Therapeutics Gene Therapy for Sickle Cell Disease Introduction
11.4.4 CRISPR Therapeutics Revenue in Gene Therapy for Sickle Cell Disease Business (2019-2024)
11.4.5 CRISPR Therapeutics Recent Development
11.5 Beam Therapeutics
11.5.1 Beam Therapeutics Company Details
11.5.2 Beam Therapeutics Business Overview
11.5.3 Beam Therapeutics Gene Therapy for Sickle Cell Disease Introduction
11.5.4 Beam Therapeutics Revenue in Gene Therapy for Sickle Cell Disease Business (2019-2024)
11.5.5 Beam Therapeutics Recent Development
11.6 Intellia Therapeutics
11.6.1 Intellia Therapeutics Company Details
11.6.2 Intellia Therapeutics Business Overview
11.6.3 Intellia Therapeutics Gene Therapy for Sickle Cell Disease Introduction
11.6.4 Intellia Therapeutics Revenue in Gene Therapy for Sickle Cell Disease Business (2019-2024)
11.6.5 Intellia Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Gene Therapy for Sickle Cell Disease Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
 Table 2. Key Players of Gene Addition Therapies
 Table 3. Key Players of Gene Editing Therapies
 Table 4. Key Players of Others
 Table 5. Global Gene Therapy for Sickle Cell Disease Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
 Table 6. Global Gene Therapy for Sickle Cell Disease Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 7. Global Gene Therapy for Sickle Cell Disease Market Size by Region (2019-2024) & (US$ Million)
 Table 8. Global Gene Therapy for Sickle Cell Disease Market Share by Region (2019-2024)
 Table 9. Global Gene Therapy for Sickle Cell Disease Forecasted Market Size by Region (2025-2030) & (US$ Million)
 Table 10. Global Gene Therapy for Sickle Cell Disease Market Share by Region (2025-2030)
 Table 11. Gene Therapy for Sickle Cell Disease Market Trends
 Table 12. Gene Therapy for Sickle Cell Disease Market Drivers
 Table 13. Gene Therapy for Sickle Cell Disease Market Challenges
 Table 14. Gene Therapy for Sickle Cell Disease Market Restraints
 Table 15. Global Gene Therapy for Sickle Cell Disease Revenue by Players (2019-2024) & (US$ Million)
 Table 16. Global Gene Therapy for Sickle Cell Disease Market Share by Players (2019-2024)
 Table 17. Global Top Gene Therapy for Sickle Cell Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Sickle Cell Disease as of 2023)
 Table 18. Ranking of Global Top Gene Therapy for Sickle Cell Disease Companies by Revenue (US$ Million) in 2023
 Table 19. Global 5 Largest Players Market Share by Gene Therapy for Sickle Cell Disease Revenue (CR5 and HHI) & (2019-2024)
 Table 20. Global Key Players of Gene Therapy for Sickle Cell Disease, Headquarters and Area Served
 Table 21. Global Key Players of Gene Therapy for Sickle Cell Disease, Product and Application
 Table 22. Global Key Players of Gene Therapy for Sickle Cell Disease, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Gene Therapy for Sickle Cell Disease Market Size by Type (2019-2024) & (US$ Million)
 Table 25. Global Gene Therapy for Sickle Cell Disease Revenue Market Share by Type (2019-2024)
 Table 26. Global Gene Therapy for Sickle Cell Disease Forecasted Market Size by Type (2025-2030) & (US$ Million)
 Table 27. Global Gene Therapy for Sickle Cell Disease Revenue Market Share by Type (2025-2030)
 Table 28. Global Gene Therapy for Sickle Cell Disease Market Size by Application (2019-2024) & (US$ Million)
 Table 29. Global Gene Therapy for Sickle Cell Disease Revenue Market Share by Application (2019-2024)
 Table 30. Global Gene Therapy for Sickle Cell Disease Forecasted Market Size by Application (2025-2030) & (US$ Million)
 Table 31. Global Gene Therapy for Sickle Cell Disease Revenue Market Share by Application (2025-2030)
 Table 32. North America Gene Therapy for Sickle Cell Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 33. North America Gene Therapy for Sickle Cell Disease Market Size by Country (2019-2024) & (US$ Million)
 Table 34. North America Gene Therapy for Sickle Cell Disease Market Size by Country (2025-2030) & (US$ Million)
 Table 35. Europe Gene Therapy for Sickle Cell Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 36. Europe Gene Therapy for Sickle Cell Disease Market Size by Country (2019-2024) & (US$ Million)
 Table 37. Europe Gene Therapy for Sickle Cell Disease Market Size by Country (2025-2030) & (US$ Million)
 Table 38. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 39. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size by Region (2019-2024) & (US$ Million)
 Table 40. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size by Region (2025-2030) & (US$ Million)
 Table 41. Latin America Gene Therapy for Sickle Cell Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 42. Latin America Gene Therapy for Sickle Cell Disease Market Size by Country (2019-2024) & (US$ Million)
 Table 43. Latin America Gene Therapy for Sickle Cell Disease Market Size by Country (2025-2030) & (US$ Million)
 Table 44. Middle East & Africa Gene Therapy for Sickle Cell Disease Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 45. Middle East & Africa Gene Therapy for Sickle Cell Disease Market Size by Country (2019-2024) & (US$ Million)
 Table 46. Middle East & Africa Gene Therapy for Sickle Cell Disease Market Size by Country (2025-2030) & (US$ Million)
 Table 47. Vertex Pharmaceuticals Company Details
 Table 48. Vertex Pharmaceuticals Business Overview
 Table 49. Vertex Pharmaceuticals Gene Therapy for Sickle Cell Disease Product
 Table 50. Vertex Pharmaceuticals Revenue in Gene Therapy for Sickle Cell Disease Business (2019-2024) & (US$ Million)
 Table 51. Vertex Pharmaceuticals Recent Development
 Table 52. Bluebird bio Company Details
 Table 53. Bluebird bio Business Overview
 Table 54. Bluebird bio Gene Therapy for Sickle Cell Disease Product
 Table 55. Bluebird bio Revenue in Gene Therapy for Sickle Cell Disease Business (2019-2024) & (US$ Million)
 Table 56. Bluebird bio Recent Development
 Table 57. Editas Medicine Company Details
 Table 58. Editas Medicine Business Overview
 Table 59. Editas Medicine Gene Therapy for Sickle Cell Disease Product
 Table 60. Editas Medicine Revenue in Gene Therapy for Sickle Cell Disease Business (2019-2024) & (US$ Million)
 Table 61. Editas Medicine Recent Development
 Table 62. CRISPR Therapeutics Company Details
 Table 63. CRISPR Therapeutics Business Overview
 Table 64. CRISPR Therapeutics Gene Therapy for Sickle Cell Disease Product
 Table 65. CRISPR Therapeutics Revenue in Gene Therapy for Sickle Cell Disease Business (2019-2024) & (US$ Million)
 Table 66. CRISPR Therapeutics Recent Development
 Table 67. Beam Therapeutics Company Details
 Table 68. Beam Therapeutics Business Overview
 Table 69. Beam Therapeutics Gene Therapy for Sickle Cell Disease Product
 Table 70. Beam Therapeutics Revenue in Gene Therapy for Sickle Cell Disease Business (2019-2024) & (US$ Million)
 Table 71. Beam Therapeutics Recent Development
 Table 72. Intellia Therapeutics Company Details
 Table 73. Intellia Therapeutics Business Overview
 Table 74. Intellia Therapeutics Gene Therapy for Sickle Cell Disease Product
 Table 75. Intellia Therapeutics Revenue in Gene Therapy for Sickle Cell Disease Business (2019-2024) & (US$ Million)
 Table 76. Intellia Therapeutics Recent Development
 Table 77. Research Programs/Design for This Report
 Table 78. Key Data Information from Secondary Sources
 Table 79. Key Data Information from Primary Sources
 Table 80. Authors List of This Report


List of Figures
 Figure 1. Gene Therapy for Sickle Cell Disease Picture
 Figure 2. Global Gene Therapy for Sickle Cell Disease Market Size Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Gene Therapy for Sickle Cell Disease Market Share by Type: 2023 VS 2030
 Figure 4. Gene Addition Therapies Features
 Figure 5. Gene Editing Therapies Features
 Figure 6. Others Features
 Figure 7. Global Gene Therapy for Sickle Cell Disease Market Size by Application (2024-2030) & (US$ Million)
 Figure 8. Global Gene Therapy for Sickle Cell Disease Market Share by Application: 2023 VS 2030
 Figure 9. Children and Adolescents Case Studies
 Figure 10. Adults Case Studies
 Figure 11. Gene Therapy for Sickle Cell Disease Report Years Considered
 Figure 12. Global Gene Therapy for Sickle Cell Disease Market Size (US$ Million), Year-over-Year: 2019-2030
 Figure 13. Global Gene Therapy for Sickle Cell Disease Market Size, (US$ Million), 2019 VS 2023 VS 2030
 Figure 14. Global Gene Therapy for Sickle Cell Disease Market Share by Region: 2023 VS 2030
 Figure 15. Global Gene Therapy for Sickle Cell Disease Market Share by Players in 2023
 Figure 16. Global Top Gene Therapy for Sickle Cell Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Sickle Cell Disease as of 2023)
 Figure 17. The Top 10 and 5 Players Market Share by Gene Therapy for Sickle Cell Disease Revenue in 2023
 Figure 18. North America Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 19. North America Gene Therapy for Sickle Cell Disease Market Share by Country (2019-2030)
 Figure 20. United States Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 21. Canada Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 22. Europe Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 23. Europe Gene Therapy for Sickle Cell Disease Market Share by Country (2019-2030)
 Figure 24. Germany Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 25. France Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 26. U.K. Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 27. Italy Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 28. Russia Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 29. Nordic Countries Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 30. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 31. Asia-Pacific Gene Therapy for Sickle Cell Disease Market Share by Region (2019-2030)
 Figure 32. China Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 33. Japan Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 34. South Korea Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 35. Southeast Asia Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 36. India Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 37. Australia Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 38. Latin America Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 39. Latin America Gene Therapy for Sickle Cell Disease Market Share by Country (2019-2030)
 Figure 40. Mexico Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 41. Brazil Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 42. Middle East & Africa Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 43. Middle East & Africa Gene Therapy for Sickle Cell Disease Market Share by Country (2019-2030)
 Figure 44. Turkey Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 45. Saudi Arabia Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 46. UAE Gene Therapy for Sickle Cell Disease Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 47. Vertex Pharmaceuticals Revenue Growth Rate in Gene Therapy for Sickle Cell Disease Business (2019-2024)
 Figure 48. Bluebird bio Revenue Growth Rate in Gene Therapy for Sickle Cell Disease Business (2019-2024)
 Figure 49. Editas Medicine Revenue Growth Rate in Gene Therapy for Sickle Cell Disease Business (2019-2024)
 Figure 50. CRISPR Therapeutics Revenue Growth Rate in Gene Therapy for Sickle Cell Disease Business (2019-2024)
 Figure 51. Beam Therapeutics Revenue Growth Rate in Gene Therapy for Sickle Cell Disease Business (2019-2024)
 Figure 52. Intellia Therapeutics Revenue Growth Rate in Gene Therapy for Sickle Cell Disease Business (2019-2024)
 Figure 53. Bottom-up and Top-down Approaches for This Report
 Figure 54. Data Triangulation
 Figure 55. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Schnitzler Syndrome Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-20K14195
Thu Oct 17 00:00:00 UTC 2024

Add to Cart

Global Gene Therapy for Sickle Cell Disease Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-9V18477
Wed Oct 16 00:00:00 UTC 2024

Add to Cart

Global Type 1 Gaucher Disease Treatment Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-7O18630
Tue Oct 15 00:00:00 UTC 2024

Add to Cart

Global Substrate Inhibition Therapy of Gaucher Disease Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-10A18470
Tue Oct 15 00:00:00 UTC 2024

Add to Cart